Crossmark

Switching from Premixed Insulin to Insulin Degludec/Insulin Aspart for the Management of Type 2 Diabetes Mellitus: Implications of a Real-World Study on Insulin Degludec Dosing

Crossref DOI link: https://doi.org/10.1007/s13300-024-01663-x

Published Online: 2024-10-26

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Yiming

Zhang, Junqing

Li, Ang https://orcid.org/0000-0003-0971-6534
License Information

Text and Data Mining valid from 2024-10-26

Version of Record valid from 2024-10-26
More Information

Article History

Received: 13 September 2024

Accepted: 15 October 2024

First Online: 26 October 2024

Declarations

:

: All authors (Yiming Wu, Junqing Zhang, and Ang Li) declare that they have no competing interests.

: This study was approved by the Ethics Committee of the Peking University First Hospital (approval number: 2024 Yan 240-001) and registered with the Chinese Clinical Trial Registry (identifier: ChiCTR2400085570). Informed consent of the patients was waived by the Ethics Committee due to the retrospective nature of the study.

Document is current

Any future updates will be listed below